You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
AAV2-ASPA-Based Metabolic Intervention for Alzheimer's Disease
SBC: ASKLEPIOS BIOPHARMACEUTICAL, INC. Topic: NIAAbstract We propose to initiate preclinical development of a gene therapeutic targeted to Alzheimer's Disease. The World Health Organization's and Alzheimer's Disease International's report on Dementia (2012) recognizes that the global burden of AlzheimerDisease is forecast to worsen significantly with prevalence predicted to double every 20 years. Interventions that could prov ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
A Diagnostic for Simultaneous Liquid and Vapor Distributions in Sprays using Filtered Rayleigh and Mie Scattering
SBC: METROLASER, INCORPORATED Topic: 07dThe understanding of how fuel evaporates and mixes when injected into an engine cylinder is of key importance for the design of cleaner, more efficient vehicles. To meet the Department of Energy & apos;s goals of improving fuel efficiency in gasoline engines by 25 percent and diesel engines by 40 percent, advanced tools for research on fuel injection dynamics are needed. Existing techniques for in ...
STTR Phase I 2014 Department of Energy -
Advanced Assessment to Accelerate Diagnostic Skill Acquisition
SBC: Parallel Consulting, LLC Topic: NIGMSDESCRIPTION (provided by applicant): Current approaches to medical education produce new physicians with insufficient clinical competency to practice effectively with limited supervision, which has serious implications for patient outcomes during hospitaloff hours. Up to 70% of patients admitted to a hospital are admitted on nights or weekends, when staffing is low and residents may be in charge o ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
A hybrid HTS/LTS Superconductor Design for High-Field Accelerator Magnets
SBC: PARTICLE BEAM LASERS, INC. Topic: 33bThe next generation of particle accelerators, including a proposed LHC upgrade, will move to higher energy and luminosity in order to continue the exploration beyond the limits of the present LHC. This will require new technologyin particular, higher field (20T or more) dipoles as well as better interaction-region quadrupoles to focus the beams at the collision points. This proposal seeks to add ...
STTR Phase I 2014 Department of Energy -
A Millimeter-wave Tunable Cavity for Ultra-sensitive Solids and Liquids DNP-NMR at Low Budget
SBC: DOTY SCIENTIFIC, INC. Topic: NIA? DESCRIPTION (provided by applicant): NMR is probably the most powerful and widely used analytical technique for structure determination and function elucidation of molecules of all types, but it suffers from low sensitivity, particularly for insoluble biological macromolecules. Dynamic Nuclear Polarization (DNP) with Magic Angle Spinning (MAS) has recently demonstrated S/N gains exceeding t ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
AML MutationCounter a tool to detect residual and recurrent leukemia
SBC: Asystbio Laboratories, LLC Topic: 102Abstract AsystBio LLC proposes to market a molecular tool kit called AML MutationCounter to count somatic mutations in genes that contribute to the development of acute myeloid leukemia AML We have developed a set of reagents and computer programs for application of next generation sequencing to count AML gene mutations The tool kit is versatile and can be used with either of the two major DNA ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
A molecularly targeted pre- and post-exposure vaccine for anthrax
SBC: VLP BIOTECH, INC. Topic: NIAIDDESCRIPTION provided by applicant We have shown that immunization of rabbits with multiple antigenic peptides MAPs displaying sequence from domain of protective antigen PA elicit antibodies specific for a linear determinant within the loop of PA that mediate potent neutralization of lethal toxin LeTx in vitro We have now shown in two separate large studies that antibodies aga ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Amplification-free megabase target-enrichment for next-generation sequencing
SBC: MISSION BIO INC Topic: NHGRIDESCRIPTION (provided by applicant): Target enrichment for next-generation sequencing enables researchers to reduce the burden of sequence data analysis, obtain higher levels of statistical significance by examining more genomes and increase sequencing coverage depth. The goal of this STTR proposal is to develop and commercialize a novel technology capable of amplification-free megabase target seq ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
A Multivalent Lyme Disease Vaccine Targeting Tick-Host-Pathogen Interactions
SBC: L2 DIAGNOSTICS LLC Topic: NIAIDDESCRIPTION provided by applicant This proposal seeks to develop a novel vaccine against Lyme disease by targeting Ixodes scapularis proteins critical for Borrelia burgdorferi transmission from the tick to mammalian host Earlier work has identified four tick proteins Salp TRE tHRF and TSLPI that facilitate different steps of spirochete transmission and immunity against these protein ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
An integrative multi phenotype pipeline for drug evaluation pharmacogenomics and attribute prediction
SBC: PHENVOGEN LLC Topic: 300PROJECT SUMMARY The process of drug discovery is costly and many promising compounds fail during clinical trials By then expenses upward of $ million dollars per failed drug may have incurred and these financial risks hamper research efforts and ultimately reduce the availability of treatment options In this research proposal we are using systematic approaches to map the relationships be ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health